- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOADAPTIVES Aktie jetzt für 0€ handeln | |||||
| 23.09. | BioAdaptives, Inc.: BioAdaptives Highlights Michael Bisping's MyndMed Routine in UFC 331 Pre-Show Instagram Video | 443 | ACCESS Newswire | UFC Hall of Famer and MyndSystem brand ambassador shares how the daytime formula fits into his preparation for live broadcasts, commentary, and podcasting. LAS VEGAS, NV / ACCESS Newswire / September... ► Artikel lesen | |
| 03.09. | BioAdaptives, Inc.: BioAdaptives Confirms First Commercial Orders of XcellaraHeart and Outlines Capital Restructuring Progress | 548 | ACCESS Newswire | Initial XcellaraHeart orders ship next week, marking the commercial launch of the Xcellara cellular wellness platform; Company prepares XcellaraResilience for October launch and highlights the retirement... ► Artikel lesen | |
| 31.08. | BioAdaptives, Inc.: UFC Hall of Famer Michael Bisping Joins BioAdaptives to Champion MyndSystem | 370 | ACCESS Newswire | Former UFC middleweight champion and current broadcaster will help promote MyndSystem as part of a disciplined day-and-night performance routine LAS VEGAS, NV / ACCESS Newswire / August 31, 2026 / BioAdaptives... ► Artikel lesen | |
| 19.08. | BIOADAPTIVES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | BIOADAPTIVES, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 13.08. | BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure Update | 404 | ACCESS Newswire | Company outlines adjustments to public float, lender lock-up and leak-out agreements, and growth-funding structure. LAS VEGAS, NV / ACCESS Newswire / August 13, 2026 / BioAdaptives, Inc. (OTCID:BDPT)... ► Artikel lesen | |
| 12.08. | BioAdaptives, Inc.: BioAdaptives Inc. Introduces XcellaraHeart: the World's First Stem Cell Mobilizer with a Targeted Cardiac Homing Signal | 335 | ACCESS Newswire | The flagship product of the new Xcellara cellular wellness platform is backed by a randomized, double-blind, placebo-controlled human clinical trial that showed an average increase of 268.8% in circulating... ► Artikel lesen | |
| 04.08. | BioAdaptiveas, Inc.: BioAdaptives Explains the Scientific Basis of the Dual-Action Xcellara "Supply and Direction" Platform | 294 | ACCESS Newswire | The Platform integrates clinically researched stem and progenitor cell mobilization with ingredients that have been studied for their roles in tissue signaling pathways. LAS VEGAS, NV / ACCESS Newswire... ► Artikel lesen | |
| 03.08. | BioAdaptives, Inc.: BioAdaptives Inc. Opens Commercial Ordering Window for XcellaraHeart Cellular Wellness Formula | 299 | ACCESS Newswire | Retirement of Largest Outstanding Convertible Debt Clears Runway for High-Growth E-Commerce Rollout of a Targeted Stem Cell Platform LAS VEGAS, NV / ACCESS Newswire / August 3, 2026 / BioAdaptives,... ► Artikel lesen | |
| 30.07. | BioAdaptives, Inc.: BioAdaptives Inc. Eliminates Major Market Overhang by Retiring the Debt of the Largest Convertible Commercial Investor | 707 | ACCESS Newswire | Strategic transaction alleviates dilutive pressure, showcasing financial strength and aligning shareholder value prior to product launches. LAS VEGAS, NV / ACCESS Newswire / July 30, 2026 / BioAdaptives... ► Artikel lesen | |
| 29.07. | BioAdaptives, Inc.: BioAdaptives Inc. Reports Scaling of E-Commerce Footprint and Consumer Reach for MyndSystem Nootropic Platform | 925 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / July 29, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, today announced a significant expansion of its digital storefront... ► Artikel lesen | |
| 23.07. | BioAdaptives Inc. Announces Operational Readiness and Completion of the Commercial Supply Chain for Upcoming Product Launches | 241 | GlobeNewswire (Europe) | LAS VEGAS, July 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC: BDPT), a developer of science-driven wellness products, today announces the successful completion of its commercial... ► Artikel lesen | |
| 16.07. | BioAdaptives Inc.: BioAdaptives Outlines Xcellara Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness | 247 | GlobeNewswire (Europe) | LAS VEGAS, July 16, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT) today outlined the scientific strategy behind its Xcellara cellular wellness platform ahead of the August 1,... ► Artikel lesen | |
| 15.07. | BioAdaptives Inc.: BioAdaptives Inc. Announces XcellaraHeart, a Cardiovascular Wellness Formula Built on Xcellara's Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells | 206 | GlobeNewswire (Europe) | LAS VEGAS, July 15, 2026 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives® Inc. (OTC: BDPT), developer of the Xcellara line of stem cell mobilization supplements, today announced the upcoming commercial... ► Artikel lesen | |
| 25.06. | BioAdaptives Inc.: BioAdaptives Completes MyndSystem Platform with TruShield Certification of MyndRenew, Securing Full WADA Compliance for Professional Athletes and Expanding Market Opportunity | 442 | GlobeNewswire (Europe) | LAS VEGAS, June 25, 2026 (GLOBE NEWSWIRE) -- via IBN - BioAdaptives, Inc. (OTC: BDPT), the parent company of MyndSystem, today announced that its nighttime repair formula, MyndRenew, has received... ► Artikel lesen | |
| 20.05. | BioAdaptives Inc.: BioAdaptives Launches MyndSystem Website - The First Supplement Platform Designed to Support Both Daytime Cognitive Performance and Overnight Brain Recovery | 1 | GlobeNewswire (USA) | ||
| 06.05. | BioAdaptives Inc.: BioAdaptives, Inc. Launches MyndRenew to Complete the 24-Hour Brain Performance Cycle | 248 | GlobeNewswire (Europe) | LAS VEGAS, May 06, 2026 (GLOBE NEWSWIRE) -- via IBN - More than 1 in 3 American adults report insufficient sleep - a deficit that research increasingly links to measurable declines in next-day cognitive... ► Artikel lesen | |
| 28.04. | BioAdaptives Inc.: BioAdaptives introduces MyndSystem, an integrated Neuro-Performance & Repair system for day and night | 1 | GlobeNewswire (USA) |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,820 | -0,02 % | Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur | DJ Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur
DOW JONES--Der Finanzinvestor EQT will einem Agenturbericht zufolge den Diagnostikspezialisten Qiagen übernehmen. Wie... ► Artikel lesen | |
| DISC MEDICINE | 75,94 | -0,08 % | Jefferies raises Disc Medicine stock price target on drug opportunity | ||
| ENLIVEN THERAPEUTICS | 41,820 | 0,00 % | H.C. Wainwright hebt Kursziel für Enliven Therapeutics auf 73 $ an | ||
| CG ONCOLOGY | 62,24 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| TANGO THERAPEUTICS | 26,990 | +0,04 % | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? | ||
| PRAXIS PRECISION MEDICINES | 256,86 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,840 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| ABSCI | 10,040 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| NURIX THERAPEUTICS | 26,000 | -0,08 % | H.C. Wainwright raises Nurix stock price target on strong revenue | ||
| SUMMIT THERAPEUTICS | 15,825 | -0,03 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 19,120 | 0,00 % | ArriVent BioPharma, Inc. - 8-K, Current Report | ||
| RAPPORT THERAPEUTICS | 25,060 | 0,00 % | Jones Trading raises Rapport Therapeutics price target on RAP-219 trial wins | ||
| ARCUS BIOSCIENCES | 19,080 | -0,03 % | Arcus Biosciences prices $250 million stock offering at $17.50 | ||
| KYMERA THERAPEUTICS | 112,56 | -0,06 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,640 | 0,00 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast |
BIOADAPTIVES INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOADAPTIVES INC finden Sie auf Wallstreet Online.